Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 6/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.35 |
| ▸ | MASP2 | O00187 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | F9 | P00740 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23201164 | 0.98 | ROCK1 (0.45) | ROCK1AURKBIDO1LOXL2KLKB1 | |
| SCHEMBL7534371 | 0.93 | ROCK1 (0.41) | ROCK1AURKBIDO1LOXL2KLKB1 | |
| Methylsulfanylmethane SCHEMBL7534377 | 0.92 | ROCK1 (0.41) | ROCK1AURKBIDO1LOXL2KLKB1 | |
| Trifluoroacetic Acid SCHEMBL30386438 | 0.85 | AURKB (0.43) | ROCK1AURKBIDO1KLKB1MAP4K1 | |
| SCHEMBL17442864 | 0.85 | ROCK1 (0.42) | ROCK1AURKBIDO1LOXL2CA12 | |
| Hydrochloric Acid SCHEMBL17442621 | 0.84 | ROCK1 (0.41) | ROCK1AURKBIDO1LOXL2CA12 | |
| SCHEMBL12012754 | 0.84 | NOS3 (0.39) | IDO1KLKB1MAP4K1MASP2F9 | |
| SCHEMBL29673224 | 0.80 | CHRNB2 (0.40) | ROCK1LOXL2CA12CA1CA2 | |
| SCHEMBL13486443 | 0.80 | IKBKE (0.43) | ROCK1AURKBIDO1KLKB1MAP4K1 | |
| SCHEMBL21596776 | 0.80 | LMNA (0.40) | IDO1KLKB1MAP4K1MASP2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-3788039-B1 | FACTOR XIIA INHIBITORS | UNIV LEEDS INNOVATIONS LTD (GB) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210087172-A1 | FACTOR XIIa INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210087172-A1 | FACTOR XIIa INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2021-03-25 | — | — | US | disclosed |
| EP-3788039-A1 | FACTOR XIIA INHIBITORS | University of Leeds (GB) | 2021-03-10 | — | — | EP | disclosed |
| CN-112204023-A | Factor XIIa inhibitors | 利兹大学 | 2021-01-08 | — | — | CN | disclosed |
| US-20050085517-A1 | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | LES LABORATOIRES SERVIER (FR) | 2005-04-21 | — | — | US | disclosed |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. | 2004-12-16 | — | — | US | disclosed |
| EP-1476421-A2 | NOVEL AMINO ACID DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID DERIVATIVE | LES LABORATOIRES SERVIER (FR) | 2004-11-17 | — | — | EP | disclosed |
| EP-1448534-A1 | 6-MEMBERED UNSATURATED HETEROCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OFTHE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | disclosed |
| WO-2003070690-A2 | NOVEL AMINO ACID DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID DERIVATIVE | LES LABORATOIRES SERVIER (FR) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003029224-A1 | 6-MEMBERED UNSATURATED HETEROCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
| US-6376499-B1 | PIPERAZINE-AMIDE COMPOUND WITH ANTICOAGULANT ACTIVITY | MERCK & CO., INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1124823-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026210-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | ROCK1 3348/4885AURKB 4489/4885IDO1 3703/4885 |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ROCK1 1922/4885AURKB 1800/4885IDO1 3923/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ROCK1 1922/4885AURKB 1800/4885IDO1 3923/4885 |
| US-20050085517-A1 | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | ARGLU1, PNISR, ATIC | ROCK1 2956/4885AURKB 3500/4885IDO1 2455/4885 |
| US-20210087172-A1 | FACTOR XIIa INHIBITORS | F11, F13B, F12 | ROCK1 432/4885AURKB 3487/4885IDO1 2712/4885 |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | TFPI, F12, SPINT2 | ROCK1 1751/4885AURKB 2863/4885IDO1 1412/4885 |
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, TFPI2 | ROCK1 3738/4885AURKB 1757/4885IDO1 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.